Pharma BD Deal Intelligence
Gilead's 2011 Calistoga buy delivered idelalisib to market as Zydelig by 2014, but a 2016 safety scare forcing six trial halts and abandoned confirmatory studies gutted it—Gilead withdrew the follicular lymphoma and SLL indications in 2022, leaving a narrow, third-line CLL product that never built the broad oncology franchise the deal promised.
Frames the buyout as a strategic expansion into oncology and inflammation, highlighting Calistoga's first-mover clinical validation of PI3K-delta inhibition…
Leerink Swann analyst Joshua Schimmer called CAL-101 'one of the more promising emerging oncology assets.'
Gilead voluntarily withdrew Zydelig's FL and SLL indications in May 2022 after failing to complete required post-marketing confirmatory studies, leaving CLL…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead acquired Calistoga for $375M upfront plus up to $225M in milestones. Lead asset CAL-101 (idelalisib) was an oral PI3K-delta inhibitor in clinical development for B-cell malignancies; later approved as Zydelig in 2014.
Assessment window: 10yr post-close.
23K US cases/yr · $358M Cumulative Zydelig (idelalisib) sales through Q1 2017
CLL is the most common adult leukemia in the US, characterized by clonal expansion of mature B-lymphocytes; iNHL encompasses follicular lymphoma and small lymphocytic lymphoma — slow-growing B-cell lymphomas often diagnosed in older adults. These malignancies are typically incurable but indolent, with long disease courses requiring sequential therapy lines.
At the February 2011 deal date, the CLL/iNHL standard-of-care was rituximab plus chemotherapy (FCR/BR regimens) from Roche/Genentech, with bendamustine (Treanda, Cephalon) gaining share. The B-cell receptor pathway (BCR) was a hot target with three competing classes in development: PI3K-delta inhibitors (Calistoga's CAL-101, later Zydelig), BTK inhibitors (Pharmacyclics' ibrutinib, partnered with J&J in December 2011 for $975M), and SYK inhibitors (Rigel's fostamatinib). Idelalisib became the first PI3K-delta inhibitor approved (July 2014) for CLL in combination with rituximab, and as monotherapy for relapsed FL and SLL — but Imbruvica (ibrutinib) launched ~9 months earlier (November 2013) and rapidly captured the dominant share of the B-cell malignancy market. Zydelig was further hobbled by FDA-mandated REMS and a 2016 halt of six combination trials due to infections and deaths, then voluntary withdrawal of FL/SLL indications in May 2022. Subsequent BTK inhibitor entries (acalabrutinib/Calquence, AstraZeneca; zanubrutinib/Brukinsa, BeiGene) and BCL2 inhibitor venetoclax (Venclexta, AbbVie/Roche) further marginalized the PI3K-delta class. The Calistoga deal mattered because it gave Gilead a first-in-class oncology asset and seeded what became its broader hematology franchise (later Kite/Yescarta), but Motley Fool retrospectively scored the Calistoga deal a 'Grade D' given Zydelig's underperformance versus the $375M upfront / $225M milestone investment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Calistoga Pharmaceuticals, Inc. (this deal) | 2011 | $600M | 35 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2011 deals · Gilead Sciences Inc. deals · Hematology deals